Safety and Tolerability

GI adverse events, dose-dependent patterns, and Phase 3 mitigation strategies

The Tolerability Challenge

Like all GLP-1 receptor agonists, survodutide triggers gastrointestinal side effects. The glucagon component adds its own profile. This unit maps the adverse event landscape from Phase 2 data, identifies the dose-dependent patterns, and explains the escalation strategies designed to improve tolerability in Phase 3.

Interactive Safety Chart

Compare adverse event frequencies across dose groups and time points.

adverse event frequency chart

Knowledge Check

Test your understanding of survodutide's safety profile.

Practice

Apply safety and tolerability concepts before moving to dosing protocols.